Equity Field Notes from temporal sources

[DanWebzster]

MESO (update)

Ph3 results for children with steroid refractory aGVHD were positive.

Considering there is no approved treatments for this condition chances are good that MESO's treatment will receive an accelerated pathway.

3/31/18 cash = $59.5mn, but they have a non-dilutive credit facility

I expect this to be a profitable run-up into FDA approval.